Dianthus Therapeutics Files S-1/A Amendment

TL;DR

<b>Dianthus Therapeutics, Inc. has filed an S-1/A amendment, updating its registration statement.</b>

AI Summary

Dianthus Therapeutics, Inc. /DE/ (DNTH) filed a Amended IPO Registration (S-1/A) with the SEC on February 7, 2024. Dianthus Therapeutics, Inc. filed an S-1/A amendment on February 7, 2024. The company is incorporated in Delaware and has its principal executive offices in New York, NY. Ryan Savitz is listed as the Chief Financial Officer. The filing is for a registration statement under the Securities Act of 1933. The company was formerly known as Magenta Therapeutics, Inc. before a name change on November 21, 2016.

Why It Matters

For investors and stakeholders tracking Dianthus Therapeutics, Inc. /DE/, this filing contains several important signals. This amendment provides updated information for potential investors regarding the company's securities. The filing indicates Dianthus Therapeutics is a smaller reporting company and a non-accelerated filer, suggesting a certain stage of development.

Risk Assessment

Risk Level: — Dianthus Therapeutics, Inc. /DE/ shows moderate risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step for companies planning to offer securities, and does not inherently indicate significant positive or negative developments.

Analyst Insight

Monitor for further filings related to the offering to understand the specific securities being registered and their terms.

Key Numbers

• 2024-02-07 — Filing Date (Date of S-1/A filing)
• 333-274863 — Registration Number (SEC registration number)
• 2016-11-21 — Name Change Date (Date of former company name change)

Key Players & Entities

• Dianthus Therapeutics, Inc. (company) — Registrant
• Delaware (location) — State of incorporation
• New York, NY (location) — Principal executive offices
• Ryan Savitz (person) — Chief Financial Officer
• Magenta Therapeutics, Inc. (company) — Former company name
• Securities Act of 1933 (regulatory) — Act under which registration is filed

Forward-Looking Statements

• Dianthus Therapeutics will initiate a public offering of securities within the next 12 months. (Dianthus Therapeutics, Inc.) — medium confidence, target: 2025-02-07

FAQ

Industry Context

The filing pertains to a company in the pharmaceutical preparations industry, as indicated by its SIC code.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the securities being offered.
2. Track subsequent SEC filings for updates on the offering's progress.
3. Research the company's business and financial status given its classification as a smaller reporting company.

Key Dates

• 2024-02-07: S-1/A Filing — Amendment to registration statement filed

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement.

Key Financial Figures

• $0.001 — 6,988 shares of common stock, par value $0.001 per share (the Common Stock and, such s
• $20.20 — ed sales price for our Common Stock was $20.20 per share. An investment in our secur

Filing Documents

• d602978ds1a.htm (S-1/A) — 2109KB
• d602978dex51.htm (EX-5.1) — 7KB
• d602978dex211.htm (EX-21.1) — 2KB
• d602978dex231.htm (EX-23.1) — 1KB
• d602978dexfilingfees.htm (EX-FILING FEES) — 38KB
• g602978g0205185306051.jpg (GRAPHIC) — 2KB
• g602978g04g04.jpg (GRAPHIC) — 33KB
• g602978g04g06.jpg (GRAPHIC) — 80KB
• g602978g04g07.jpg (GRAPHIC) — 63KB
• g602978g04g08.jpg (GRAPHIC) — 151KB
• g602978g04g09.jpg (GRAPHIC) — 71KB
• g602978g04g10.jpg (GRAPHIC) — 54KB
• g602978g05g05.jpg (GRAPHIC) — 77KB
• g602978g34g34.jpg (GRAPHIC) — 73KB
• 0001193125-24-026760.txt (&nbsp;) — 2958KB

RISK FACTORS

RISK FACTORS 8 BUSINESS COMBINATION OF DIANTHUS AND OPCO 48 PRIVATE PLACEMENTS OF SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS 51 MARKET PRICE AND DIVIDEND INFORMATION 53

USE OF PROCEEDS

USE OF PROCEEDS 54

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 55 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 76

BUSINESS

BUSINESS 77 MANAGEMENT 118

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 125

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 134 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 138 SELLING STOCKHOLDERS 143 PLAN OF DISTRIBUTION 149

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 151 LEGAL MATTERS 157 EXPERTS 157 WHERE YOU CAN FIND MORE INFORMATION 157 INDEX TO FINANCIAL STATEMENTS F-1 Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC using a shelf registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, offer and sell the securities described in this prospectus in one or more offerings. Information about the Selling Stockholders may change over time. This prospectus provides you with a general description of the shares the Selling Stockholders may offer. Each time the Selling Stockholders sell our shares of Common Stock using this prospectus, to the extent necessary and required by law, we will provide a prospectus supplement that will contain specific information about the terms of that offering, including the number of shares of Common Stock being offered, the manner of distribution, the identity of any underwriters or other counterparties and other specific terms related to the offering. The prospectus supplement may also add, update or change information contained in this prospectus. To the extent that any statement made in a prospectus supplement is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus supplement. You should read this prospectus and any applicable prospectus supplement before making an investment in shares of our Common Stock. See Where You Can Find More Information for more information. Neither we nor the Selling Stockholders have authorized anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provid

Use of Proceeds

Use of Proceeds We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale by the Selling Stockholders of the Common Stock. Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. See the section titled Use of Proceeds located elsewhere in this prospectus.

Risk Factors

Risk Factors You should read the section titled Risk Factors located elsewhere in this prospectus for a discussion of the risks, uncertainties and other factors to consider carefully before deciding to invest in shares of our Common Stock. Nasdaq Capital Market symbol: Our Common Stock is listed on The Nasdaq Capital Market under the symbol DNTH. We do not intend to apply for listing of the Pre-Funded Warrants on any securities exchange or nationally recognized trading system. Except as indicated otherwise, all share numbers related to our Common Stock disclosed in this prospectus have been adjusted on a post-reverse split basis. For additional information concerning the offering, see the section titled Plan of Distribution . SUMMARY OF RISK FACTORS We have a limited operating history, have not completed any late-stage clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability; We will require substantial additional capital to finance our operations in the future. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate clinical trials, product development programs or future commercialization efforts; We have incurred significant losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have no products for sale, have not generated any product revenue and may never generate product revenue or become profitable; 5 Table of Contents We face competition from entities that have developed or may develop programs for the diseases we plan to address with DNTH103 or other product candidates; DNTH103 and our other programs are in early stages of development and may fail in development or suffer delays that materially and adversely affect their commercial viability.

View Full Filing

View this S-1/A filing on SEC EDGAR